American Heart Journal
Volume 158, Issue 5 , Pages 713-718 , November 2009

Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST)

  • Willem Dewilde, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Willem Dewilde, MD, Sint Antonius Hospital, Nieuwegein, The Netherlands, Koekoekslaan 1, 3435 CM Nieuwegein.
    • ,
  • Jurriën Ten Berg, MD, PhD, FACC

Received 14 February 2009 ,Accepted 11 September 2009.

References 

  1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines , Society of Cardiovascular Anesthesiologists , Society for Cardiovascular Angiography and Interventions , et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006;114:e84–e231
  2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27:1979–2030
  3. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156–175
  4. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–732
  5. Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004;147:463–467
  6. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671
  7. Rubboli A, Milandri M, Castelvetri , et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 2005;104:101–106[Epub 2005 Jul 12]
  8. ACTIVE Writing Group on behalf of the ACTIVE Investigators , Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912
  9. Lip GY. Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. BMJ. 2008;a840:337
  10. Ruiz-Nodar JM, Marín F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818–825
  11. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40:428–436[Review]
  12. Rubboli A, Halperin JL. Pro: “antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions”. Thromb Haemost. 2008;100:752–753
  13. Roldán V, Marín F. Contra: “antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions”. Not for everybody. Thromb Haemost. 2008;100:754–755
  14. Dewilde W, Ten Berg JM. the antithrombotic dilemma future. Cardiology. 2007;3:511–513
  15. Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005;165:784–789
  16. Mattichak SJ, Reed PS, Gallagher MJ, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol. 2005;18:163–166
  17. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators , Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  18. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162–164
  19. Porter A, Konstantino Y, Iakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:56–61
  20. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–260
  21. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–944
  22. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009;360:411–413
  23. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362
  24. Simon T, Verstuyft C, Mary-Krause M, et al., for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST MI) Investigators  Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375
  25. ten Berg JM, Hutten BA, Kelder JC, et al. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation. 2001;103:2042–2047
  26. Silber S, Albertsson P, Avilés FF, et al., for the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.Guidelines for percutaneous coronary interventions  The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–847
  27. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation. 2009;119:1330–1352
  28. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–154
  29. The Gusto Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  30. Cutlip DE, Windecker S, Mehran R, et al., for the Academic Research Consortium  Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351

 RCT no. NCT00769938.

PII: S0002-8703(09)00718-2

doi: 10.1016/j.ahj.2009.09.001

American Heart Journal
Volume 158, Issue 5 , Pages 713-718 , November 2009

Article Tools

* Image Usage & Resolution